ES2676905T3 - Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico - Google Patents
Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico Download PDFInfo
- Publication number
- ES2676905T3 ES2676905T3 ES15709324.6T ES15709324T ES2676905T3 ES 2676905 T3 ES2676905 T3 ES 2676905T3 ES 15709324 T ES15709324 T ES 15709324T ES 2676905 T3 ES2676905 T3 ES 2676905T3
- Authority
- ES
- Spain
- Prior art keywords
- hydroxypyridazin
- ethyl
- hydroxy
- trifluoromethyl
- pyridazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1403944.0A GB201403944D0 (en) | 2014-03-06 | 2014-03-06 | New use |
| GB201403944 | 2014-03-06 | ||
| PCT/GB2015/050654 WO2015132608A1 (en) | 2014-03-06 | 2015-03-06 | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2676905T3 true ES2676905T3 (es) | 2018-07-26 |
Family
ID=50554599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15709324.6T Active ES2676905T3 (es) | 2014-03-06 | 2015-03-06 | Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico |
Country Status (32)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| US10118917B2 (en) | 2014-04-29 | 2018-11-06 | E I Du Pont De Nemours And Company | Pyridazinone herbicides |
| TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
| US11213030B2 (en) | 2017-06-30 | 2022-01-04 | Fmc Corporation | 4-(3,4-dihydronaphth-1-yl or 2H-chromen-4-yl)-5-hydroxy-2H-pyradizin-3-ones as herbicides |
| CN112569217B (zh) * | 2019-09-30 | 2022-04-22 | 厦门大学 | 戊酸衍生物在治疗遗传性小脑共济失调中的应用 |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| CA3209781A1 (en) | 2021-03-01 | 2022-09-09 | Takeda Pharmaceuticals Company Limited | Use of luvadaxistat for the treatment of cognitive impairment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE321553T1 (de) * | 1998-06-10 | 2006-04-15 | Meiji Seika Kaisha | Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie |
| WO2003047558A2 (en) * | 2001-12-03 | 2003-06-12 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| JO3115B1 (ar) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
-
2014
- 2014-03-06 GB GBGB1403944.0A patent/GB201403944D0/en not_active Ceased
-
2015
- 2015-03-05 TW TW104106995A patent/TW201534591A/zh unknown
- 2015-03-06 US US15/123,796 patent/US20170014407A1/en not_active Abandoned
- 2015-03-06 GE GEAP201514284A patent/GEP20196984B/en unknown
- 2015-03-06 TR TR2018/09537T patent/TR201809537T4/tr unknown
- 2015-03-06 HR HRP20181082TT patent/HRP20181082T1/hr unknown
- 2015-03-06 MX MX2016010524A patent/MX2016010524A/es unknown
- 2015-03-06 WO PCT/GB2015/050654 patent/WO2015132608A1/en not_active Ceased
- 2015-03-06 DK DK15709324.6T patent/DK3113778T3/en active
- 2015-03-06 KR KR1020167027639A patent/KR20160126081A/ko not_active Withdrawn
- 2015-03-06 EA EA201691566A patent/EA036438B1/ru unknown
- 2015-03-06 MY MYPI2016703081A patent/MY202127A/en unknown
- 2015-03-06 SI SI201530291T patent/SI3113778T1/en unknown
- 2015-03-06 UA UAA201608758A patent/UA123352C2/uk unknown
- 2015-03-06 SG SG11201607106YA patent/SG11201607106YA/en unknown
- 2015-03-06 SM SM20180367T patent/SMT201800367T1/it unknown
- 2015-03-06 RS RS20180927A patent/RS57594B1/sr unknown
- 2015-03-06 MA MA39315A patent/MA39315A1/fr unknown
- 2015-03-06 ES ES15709324.6T patent/ES2676905T3/es active Active
- 2015-03-06 CN CN201580012352.1A patent/CN106102743A/zh active Pending
- 2015-03-06 LT LTEP15709324.6T patent/LT3113778T/lt unknown
- 2015-03-06 AU AU2015225954A patent/AU2015225954B2/en not_active Ceased
- 2015-03-06 EP EP15709324.6A patent/EP3113778B1/en active Active
- 2015-03-06 PL PL15709324T patent/PL3113778T3/pl unknown
- 2015-03-06 CA CA2940342A patent/CA2940342A1/en not_active Abandoned
- 2015-03-06 JP JP2016555645A patent/JP6510549B2/ja not_active Expired - Fee Related
- 2015-03-06 PT PT157093246T patent/PT3113778T/pt unknown
-
2016
- 2016-07-06 ZA ZA2016/04611A patent/ZA201604611B/en unknown
- 2016-08-23 IL IL247435A patent/IL247435A0/en active IP Right Grant
- 2016-08-25 CL CL2016002151A patent/CL2016002151A1/es unknown
- 2016-09-06 PH PH12016501751A patent/PH12016501751A1/en unknown
-
2018
- 2018-08-10 CY CY20181100843T patent/CY1120573T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2676905T3 (es) | Derivados de piridazina para su uso en la prevención o tratamiento de una trastorno atáxico | |
| US12201631B2 (en) | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome | |
| US20220040150A1 (en) | Intravenous dmt administration method for dmt-assisted psychotherapy | |
| JP5875191B2 (ja) | Ｃｍｔ及び関連障害を処置するための新たな組成物 | |
| TWI291871B (en) | Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning | |
| JP5605659B2 (ja) | 細胞保護剤 | |
| ES2323451T3 (es) | Tratamiento para el trastorno de hiperactividad con deficit de atencion. | |
| US20220273662A1 (en) | Use of sildenafil and rock inhibitors for treating stroke or sequelae following stroke | |
| Barr et al. | Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats | |
| Oksman et al. | Behavioural and neurochemical response of α-synuclein A30P transgenic mice to the effects of L-DOPA | |
| Brown et al. | Extinction, reacquisition, and rapid forgetting of eyeblink conditioning in developing rats | |
| HK1230925A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| EP4203948A1 (en) | Compositions and uses thereof | |
| Gombos et al. | Long-term enhancement of entorhinal-dentate evoked potentials followingmodified'ECS in the rat | |
| US20230062537A1 (en) | Therapy of oxygen pulses for treating neurodegenerative disorders such as Parkinson Disease (PD), Alzheimer’s Disease (AD), Amiotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) and other dementias, and Lymphedema, Arthritis and Depression | |
| Masseck et al. | The optokinetic reaction in foveate and afoveate geckos | |
| Yang | A study of ocular dominance plasticity: probing the molecular mechanisms and exploring its effect on functional connectivity | |
| EP4208161A1 (en) | Compositions and uses thereof | |
| Wortinger | What happens after successful CPCR. | |
| Hunter | Glutamate and escape performance in a neurometabolic stress conception of helplessness | |
| Sanberg | An animal model of Huntington’s disease: behavioral, pharmacological and morphological changes following intrastriatal injections of kainic acid | |
| Heinz et al. | How much fear is in anxiety? | |
| McGraw | NEOCORTICAL AND OTHER MODULATING INFLUENCES ON THE'IMMOBILITY REFLEX' |